Related Experiment Videos
Dehydroepiandrosterone in systemic lupus erythematosus
1Department of Rheumatology, Karolinska Hospital, Stockholm, Sweden. ronaldv@rheum.ks.se
Rheumatic Diseases Clinics of North America
|April 18, 2000
Summary
Dehydroepiandrosterone (DHEA) shows promise for treating Systemic Lupus Erythematosus (SLE), potentially reducing corticosteroid needs and improving symptoms. Further research is needed for bone and cognitive benefits, with mild skin rash and lower HDL cholesterol as side effects.
Area of Science:
- Rheumatology
- Endocrinology
- Immunology
Background:
- Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with significant morbidity.
- Current treatments for SLE often involve corticosteroids, which have considerable side effects.
- Dehydroepiandrosterone (DHEA) is an endogenous steroid hormone with immunomodulatory properties.
Purpose of the Study:
- To evaluate the efficacy and safety of DHEA as a therapeutic agent for SLE.
- To assess DHEA's impact on corticosteroid requirements and overall disease symptomatology in SLE patients.
- To explore potential benefits of DHEA on bone health and cognitive function in SLE.
Main Methods:
- Review of controlled and uncontrolled clinical trials investigating DHEA for SLE treatment.
- Inclusion of data from a large multicenter study with approximately 200 patients.
- Analysis of reported benefits, side effects, and long-term concerns associated with DHEA therapy.
Main Results:
- DHEA demonstrated promise in multiple clinical trials for SLE management.
- Key benefits include reduced need for corticosteroids and improved overall disease symptoms.
- Potential positive effects on bone protection and cognitive function warrant further investigation.
Conclusions:
- DHEA represents a promising therapeutic option for SLE, potentially reducing corticosteroid dependence.
- While generally well-tolerated, mild acneiform dermatitis is a common side effect.
- Long-term monitoring for effects on HDL cholesterol is recommended.